New England Journal of Medicine· 2014Q1
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
- 1,967citations
- Q1SCImago
- 2014year
Short summary
Bapineuzumab, an anti-amyloid-beta antibody, failed to show significant clinical benefits in two Phase 3 trials for mild-to-moderate Alzheimer's disease, with no meaningful differences in cognitive or functional scores compared to placebo.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Psychiatry and Mental health
Psychiatry and Mental healthMedicine